{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:01:14Z","timestamp":1786960874168,"version":"build-2736575974"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002353","name":"Alexandria Faculty of Medicine, Alexandria University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejphar.2023.176066","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T21:05:37Z","timestamp":1695762337000},"page":"176066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: Emphasis on gal-1\/NRP-1\/TGF-\u03b2 and gal-1\/NRP-1\/VEGFR2 pathways"],"prefix":"10.1016","volume":"959","author":[{"given":"Ashraf A.","family":"Noah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2418-453X","authenticated-orcid":false,"given":"Nesrine S.","family":"El-Mezayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-3078","authenticated-orcid":false,"given":"Samar O.","family":"El-Ganainy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inas E.","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham A.","family":"Afify","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejphar.2023.176066_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00210-018-1544-y","article-title":"Empagliflozin, SGLT 2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of Klotho expression","volume":"391","author":"Abbas","year":"2018","journal-title":"N. Schmied. Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176066_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112455","article-title":"Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: emerging approach for new application","volume":"145","author":"Abdelhamid","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.ejphar.2023.176066_bib3","doi-asserted-by":"crossref","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Abdul-Ghani","year":"2015","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"11","key":"10.1016\/j.ejphar.2023.176066_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113103","article-title":"Modeling of hypo\/hyperglycemia and their impact on breast cancer progression related molecules","volume":"9","author":"Adham","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.176066_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113677","article-title":"Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats","volume":"170","author":"Aragon-Herrera","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"29","key":"10.1016\/j.ejphar.2023.176066_bib6","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.3748\/wjg.v23.i29.5266","article-title":"Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression","volume":"23","author":"Bacigalupo","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2023.176066_bib7","series-title":"Neuropilin-1: A Feasible Link between Liver Pathologies and COVID-19","author":"Benedicto Garc\u00eda","year":"2021"},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0168-8278(85)80770-4","article-title":"Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators","volume":"1","author":"Bhathal","year":"1985","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.ejphar.2023.176066_bib9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/clinchem\/26.5.555","article-title":"Kinetic serum creatinine assays. II. A critical evaluation and review","volume":"26","author":"Bowers","year":"1980","journal-title":"Clin. Chem."},{"issue":"7","key":"10.1016\/j.ejphar.2023.176066_bib10","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1172\/JCI41203","article-title":"Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF\/TGF-\u03b2 signaling in hepatic stellate cells","volume":"120","author":"Cao","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2023.176066_bib11","series-title":"Carleton's Histological Technique","author":"Carleton","year":"1980"},{"issue":"31","key":"10.1016\/j.ejphar.2023.176066_bib12","doi-asserted-by":"crossref","first-page":"11432","DOI":"10.1073\/pnas.0403969101","article-title":"Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect","volume":"101","author":"Castro-Rivera","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.ejphar.2023.176066_bib13","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ajcp\/54.6.828","article-title":"Automated micromeasurement of urea using urease and the Berthelot reaction","volume":"54","author":"Creno","year":"1970","journal-title":"Am. J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jhep.2010.06.004","article-title":"Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension","volume":"53","author":"de Franchis","year":"2010","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3748\/wjg.v22.i4.1357","article-title":"Liver pathology of hepatitis C, beyond grading and staging of the disease","volume":"22","author":"Dhingra","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2023.176066_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106201","article-title":"Vitamin B12 as a cholinergic system modulator and blood brain barrier integrity restorer in Alzheimer's disease","volume":"174","author":"El-Mezayen","year":"2022","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejphar.2023.176066_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jconrel.2017.09.035","article-title":"Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: a novel strategy with potent efficacy in experimental liver fibrosis","volume":"266","author":"El-Mezayen","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2023.176066_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fonc.2018.00357","article-title":"Transforming growth factor-\u03b2-induced cell plasticity in liver fibrosis and hepatocarcinogenesis","volume":"8","author":"Fabregat","year":"2018","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000444551","article-title":"Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis","volume":"34","author":"Garcia-Tsao","year":"2016","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ejphar.2023.176066_bib20","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03720","article-title":"Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding","volume":"3","author":"Gelfand","year":"2014","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/carcin\/bgq281","article-title":"Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta","volume":"32","author":"Glinka","year":"2011","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41575-018-0097-3","article-title":"Hepatic microcirculation and mechanisms of portal hypertension","volume":"16","author":"Gracia-Sancho","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176066_bib77","series-title":"The novel SGLT2 inhibitor BI 10773 prevents pioglitazone-induced weight gain and further improves glycemic control in dietary-induced obese rats. Diabetes 60","first-page":"A499","author":"Grempler","year":"2011"},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib23","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.510280405","article-title":"Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats","volume":"28","author":"Gupta","year":"1998","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejphar.2023.176066_bib24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/biomedicines10051032","article-title":"Empagliflozin reduces the progression of hepatic fibrosis in a mouse model and inhibits the activation of hepatic stellate cells via the hippo signalling pathway","volume":"10","author":"Heo","year":"2022","journal-title":"Biomedicines"},{"issue":"15","key":"10.1016\/j.ejphar.2023.176066_bib25","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1091\/mbc.e09-12-1061","article-title":"VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation","volume":"22","author":"Herzog","year":"2011","journal-title":"Mol. Biol. Cell"},{"issue":"3","key":"10.1016\/j.ejphar.2023.176066_bib26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.pharep.2014.10.021","article-title":"The protective effect of curcumin administration on carbon tetrachloride (CCl4)-induced nephrotoxicity in rats","volume":"67","author":"Hismiogullari","year":"2015","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on SGLT2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"26","key":"10.1016\/j.ejphar.2023.176066_bib28","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1038\/sj.onc.1211029","article-title":"Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells","volume":"27","author":"Hsieh","year":"2008","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/biomedicines9040353","article-title":"Dulaglutide alone and in combination with empagliflozin attenuate inflammatory pathways and microbiome dysbiosis in a non-diabetic mouse model of NASH","volume":"9","author":"Hupa-Breier","year":"2021","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.ejphar.2023.176066_bib30","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/jcm8111814","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes","volume":"8","author":"Iannantuoni","year":"2019","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-15958-1","article-title":"Alleviation of liver cirrhosis and associated portal-hypertension by Astragalus species in relation to their UPLC-MS\/MS metabolic profiles: a mechanistic study","volume":"12","author":"Ibrahim","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ejphar.2023.176066_bib32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1478-3231.2011.02579.x","article-title":"Endothelial dysfunction in the regulation of cirrhosis and portal hypertension","volume":"32","author":"Iwakiri","year":"2012","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol. Metab. Syndrome"},{"issue":"2","key":"10.1016\/j.ejphar.2023.176066_bib34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s13300-020-00789-y","article-title":"Basic and clinical pharmaco-therapeutics of SGLT2 inhibitors: a contemporary update","volume":"11","author":"Kalra","year":"2020","journal-title":"Diabetes Therapy"},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib36","first-page":"543","article-title":"Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176066_bib37","series-title":"Drug Delivery Systems","first-page":"665","article-title":"Coating technologies in pharmaceutical product development","author":"Kapoor","year":"2020"},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib38","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/liv.14390","article-title":"Collagen biology and non\u2010invasive biomarkers of liver fibrosis","volume":"40","author":"Karsdal","year":"2020","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.ejphar.2023.176066_bib39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2023.176066_bib40","series-title":"Fibrosis","first-page":"91","article-title":"Mouse and rat models of induction of hepatic fibrosis and assessment of portal hypertension","author":"Klein","year":"2017"},{"issue":"8","key":"10.1016\/j.ejphar.2023.176066_bib41","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ejphar.2023.176066_bib42","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.21873\/invivo.12400","article-title":"Nuclear VEGFR-2 expression of hepatocytes is involved in hepatocyte proliferation and liver regeneration during chronic liver injury","volume":"35","author":"Lee","year":"2021","journal-title":"In Vivo"},{"key":"10.1016\/j.ejphar.2023.176066_bib43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2021.12.065","article-title":"Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease","volume":"588","author":"Lee","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib44","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.5862","article-title":"Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF\u2010A\/caveolin\u20101\/PV\u20101 signaling pathway","volume":"256","author":"Locatelli","year":"2022","journal-title":"J. Pathol."},{"issue":"21","key":"10.1016\/j.ejphar.2023.176066_bib45","doi-asserted-by":"crossref","first-page":"18938","DOI":"10.1074\/jbc.M209673200","article-title":"Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways","volume":"278","author":"Maeda","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.ejphar.2023.176066_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083168","article-title":"Severe hypoglycemia in a juvenile diabetic rat model: presence and severity of seizures are associated with mortality","volume":"8","author":"Maheandiran","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejphar.2023.176066_bib47","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jhep.2005.04.002","article-title":"VEGF-induced angiogenesis drives collateral circulation in portal hypertension","volume":"43","author":"Moreau","year":"2005","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib49","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1254\/jphs.10R37FM","article-title":"Pharmacology in health foods: improvement of vascular endothelial function by French maritime pine bark extract (Flavangenol)","volume":"115","author":"Ohkita","year":"2011","journal-title":"J. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-00997-7","article-title":"Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat","volume":"19","author":"Park","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"issue":"24","key":"10.1016\/j.ejphar.2023.176066_bib51","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejphar.2023.176066_bib52","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.3390\/ijms22105089","article-title":"Empagliflozin inhibits IL-1\u03b2-mediated inflammatory response in human proximal tubular cells","volume":"22","author":"Pirklbauer","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2023.176066_bib53","doi-asserted-by":"crossref","first-page":"F449","DOI":"10.1152\/ajprenal.00431.2018","article-title":"Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells","volume":"316","author":"Pirklbauer","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13098-015-0102-8","article-title":"Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus","volume":"7","author":"Qiang","year":"2015","journal-title":"Diabetol. Metab. Syndrome"},{"key":"10.1016\/j.ejphar.2023.176066_bib55","doi-asserted-by":"crossref","first-page":"344","DOI":"10.21608\/besps.2020.44458.1075","article-title":"Potential mechanisms underlying the renoprotective effect of empagliflozin, a novel selective sodium glucose co-transporter (SGLT) 2 inhibitor, against diabetic nephropathy in streptozotocin induced diabetic rats","author":"Said","year":"2021","journal-title":"Bulletin of Egyptian Soc. Physiolo. Sci."},{"issue":"10","key":"10.1016\/j.ejphar.2023.176066_bib56","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cell.2014.01.059","article-title":"Galectin-1 pulls the strings on VEGFR2","volume":"156","author":"Stanley","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/00365510410002742","article-title":"Reference intervals for eight enzymes in blood of adult females and males measured in accordance with the International Federation of Clinical Chemistry reference system at 37 C: part of the Nordic Reference Interval Project","volume":"64","author":"Str\u00f8mme","year":"2004","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"4","key":"10.1016\/j.ejphar.2023.176066_bib60","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jhep.2015.03.039","article-title":"Mechanisms of liver fibrosis resolution","volume":"63","author":"Tacke","year":"2015","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.ejphar.2023.176066_bib61","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.ejphar.2023.176066_bib62","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2010.07.004","article-title":"Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?","volume":"53","author":"Thabut","year":"2010","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-020-1693-3","volume":"21","author":"Thammitiyagodage","year":"2020","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-015-0291-5","article-title":"Hepatic stellate cells: central modulators of hepatic carcinogenesis","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Gastroenterol."},{"issue":"10","key":"10.1016\/j.ejphar.2023.176066_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-020-00870-8","article-title":"CD36 in atherosclerosis: pathophysiological mechanisms and therapeutic implications","volume":"22","author":"Tian","year":"2020","journal-title":"Curr. Atherosclerosis Rep."},{"issue":"8","key":"10.1016\/j.ejphar.2023.176066_bib66","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/oem.52.8.508","article-title":"Hepatic function in workers occupationally exposed to carbon tetrachloride","volume":"52","author":"Tomenson","year":"1995","journal-title":"Occup. Environ. Med."},{"issue":"11","key":"10.1016\/j.ejphar.2023.176066_bib67","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/biology9110369","article-title":"TLR9 binding to beclin 1 and mitochondrial SIRT3 by a sodium-glucose co-transporter 2 inhibitor protects the heart from doxorubicin toxicity","volume":"9","author":"Wang","year":"2020","journal-title":"Biology"},{"issue":"6","key":"10.1016\/j.ejphar.2023.176066_bib68","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"The global burden of liver disease: the major impact of China","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176066_bib69","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ebiom.2019.04.050","article-title":"Neuropilin-1 aggravates liver cirrhosis by promoting angiogenesis via VEGFR2-dependent PI3K\/Akt pathway in hepatic sinusoidal endothelial cells","volume":"43","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.ejphar.2023.176066_bib70","doi-asserted-by":"crossref","first-page":"E94","DOI":"10.1111\/hepr.12732","article-title":"Intrahepatic angiogenesis increases portal hypertension in hepatitis B patients with cirrhosis","volume":"47","author":"Wang","year":"2017","journal-title":"Hepatol. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2023.176066_bib71","first-page":"133","article-title":"Estimation of the normal range of blood glucose in rats","volume":"39","author":"Wang","year":"2010","journal-title":"J. Hyg. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-9-182","article-title":"Recurrent\/moderate hypoglycemia induces hippocampal dendritic injury, microglial activation, and cognitive impairment in diabetic rats","volume":"9","author":"Won","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.ejphar.2023.176066_bib73","first-page":"1","article-title":"Glycosylation-dependent galectin-1\/neuropilin-1 interactions promote liver fibrosis through activation of TGF-\u03b2-and PDGF-like signals in hepatic stellate cells","volume":"7","author":"Wu","year":"2017","journal-title":"Sci. Rep."},{"issue":"6801","key":"10.1016\/j.ejphar.2023.176066_bib74","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","article-title":"Vascular-specific growth factors and blood vessel formation","volume":"407","author":"Yancopoulos","year":"2000","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejphar.2023.176066_bib75","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jep.2013.05.028","article-title":"Multitargeted inhibition of hepatic fibrosis in chronic iron-overloaded mice by Salvia miltiorrhiza","volume":"148","author":"Zhang","year":"2013","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2023.176066_bib76","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hepr.12415","article-title":"Update on implications and mechanisms of angiogenesis in liver fibrosis","volume":"45","author":"Zhang","year":"2015","journal-title":"Hepatol. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923005782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923005782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:26:19Z","timestamp":1757978779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923005782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":77,"alternative-id":["S0014299923005782"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176066","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: Emphasis on gal-1\/NRP-1\/TGF-\u03b2 and gal-1\/NRP-1\/VEGFR2 pathways","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"176066"}}